Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 46

1.

Cohorts and consortia conference: a summary report (Banff, Canada, June 17-19, 2009).

Boffetta P, Colditz GA, Potter JD, Kolonel L, Robson PJ, Malekzadeh R, Seminara D, Goode EL, Yoo KY, Demers P, Gallagher R, Prentice R, Yasui Y, O'Doherty K, Petersen GM, Ulrich CM, Csizmadi I, Amankwah EK, Brockton NT, Kopciuk K, McGregor SE, Kelemen LE.

Cancer Causes Control. 2011 Mar;22(3):463-8. doi: 10.1007/s10552-010-9717-0. Epub 2011 Jan 4.

PMID:
21203821
2.

Common variants at 19p13 are associated with susceptibility to ovarian cancer.

Bolton KL, Tyrer J, Song H, Ramus SJ, Notaridou M, Jones C, Sher T, Gentry-Maharaj A, Wozniak E, Tsai YY, Weidhaas J, Paik D, Van Den Berg DJ, Stram DO, Pearce CL, Wu AH, Brewster W, Anton-Culver H, Ziogas A, Narod SA, Levine DA, Kaye SB, Brown R, Paul J, Flanagan J, Sieh W, McGuire V, Whittemore AS, Campbell I, Gore ME, Lissowska J, Yang HP, Medrek K, Gronwald J, Lubinski J, Jakubowska A, Le ND, Cook LS, Kelemen LE, Brooks-Wilson A, Massuger LF, Kiemeney LA, Aben KK, van Altena AM, Houlston R, Tomlinson I, Palmieri RT, Moorman PG, Schildkraut J, Iversen ES, Phelan C, Vierkant RA, Cunningham JM, Goode EL, Fridley BL, Kruger-Kjaer S, Blaeker J, Hogdall E, Hogdall C, Gross J, Karlan BY, Ness RB, Edwards RP, Odunsi K, Moyisch KB, Baker JA, Modugno F, Heikkinenen T, Butzow R, Nevanlinna H, Leminen A, Bogdanova N, Antonenkova N, Doerk T, Hillemanns P, Dürst M, Runnebaum I, Thompson PJ, Carney ME, Goodman MT, Lurie G, Wang-Gohrke S, Hein R, Chang-Claude J, Rossing MA, Cushing-Haugen KL, Doherty J, Chen C, Rafnar T, Besenbacher S, Sulem P, Stefansson K, Birrer MJ, Terry KL, Hernandez D, Cramer DW, Vergote I, Amant F, Lambrechts D, Despierre E, Fasching PA, Beckmann MW, Thiel FC, Ekici AB, Chen X; Australian Ovarian Cancer Study Group; Australian Cancer Study (Ovarian Cancer); Ovarian Cancer Association Consortium, Johnatty SE, Webb PM, Beesley J, Chanock S, Garcia-Closas M, Sellers T, Easton DF, Berchuck A, Chenevix-Trench G, Pharoah PD, Gayther SA.

Nat Genet. 2010 Oct;42(10):880-4. doi: 10.1038/ng.666. Epub 2010 Sep 19. Erratum in: Nat Genet. 2016 Jan;48(1):101. Brook-Wilson, Angela [corrected to Brooks-Wilson, Angela].

3.

Evaluation of candidate stromal epithelial cross-talk genes identifies association between risk of serous ovarian cancer and TERT, a cancer susceptibility "hot-spot".

Johnatty SE, Beesley J, Chen X, Macgregor S, Duffy DL, Spurdle AB, deFazio A, Gava N, Webb PM, Rossing MA, Doherty JA, Goodman MT, Lurie G, Thompson PJ, Wilkens LR, Ness RB, Moysich KB, Chang-Claude J, Wang-Gohrke S, Cramer DW, Terry KL, Hankinson SE, Tworoger SS, Garcia-Closas M, Yang H, Lissowska J, Chanock SJ, Pharoah PD, Song H, Whitemore AS, Pearce CL, Stram DO, Wu AH, Pike MC, Gayther SA, Ramus SJ, Menon U, Gentry-Maharaj A, Anton-Culver H, Ziogas A, Hogdall E, Kjaer SK, Hogdall C, Berchuck A, Schildkraut JM, Iversen ES, Moorman PG, Phelan CM, Sellers TA, Cunningham JM, Vierkant RA, Rider DN, Goode EL, Haviv I, Chenevix-Trench G; Ovarian Cancer Association Consortium; Australian Ovarian Cancer Study Group; Australian Cancer Study (Ovarian Cancer).

PLoS Genet. 2010 Jul 8;6(7):e1001016. doi: 10.1371/journal.pgen.1001016.

4.

Cancer statistics, 2010.

Jemal A, Siegel R, Xu J, Ward E.

CA Cancer J Clin. 2010 Sep-Oct;60(5):277-300. doi: 10.3322/caac.20073. Epub 2010 Jul 7. Erratum in: CA Cancer J Clin. 2011 Mar-Apr;61(2):133-4.

5.

Genetic dissection of intermediate phenotypes as a way to discover novel cancer susceptibility alleles.

Carvajal-Carmona LG.

Curr Opin Genet Dev. 2010 Jun;20(3):308-14. doi: 10.1016/j.gde.2010.03.013. Epub 2010 Apr 24. Review.

PMID:
20456939
6.

Variation at 8q24 and 9p24 and risk of epithelial ovarian cancer.

White KL, Sellers TA, Fridley BL, Vierkant RA, Phelan CM, Tsai YY, Kalli KR, Berchuck A, Iversen ES, Hartmann LC, Liebow M, Armasu S, Fredericksen Z, Larson MC, Duggan D, Couch FJ, Schildkraut JM, Cunningham JM, Goode EL.

Twin Res Hum Genet. 2010 Feb;13(1):43-56. doi: 10.1375/twin.13.1.43.

7.

Risk of ovarian cancer and inherited variants in relapse-associated genes.

Peedicayil A, Vierkant RA, Hartmann LC, Fridley BL, Fredericksen ZS, White KL, Elliott EA, Phelan CM, Tsai YY, Berchuck A, Iversen ES Jr, Couch FJ, Peethamabaran P, Larson MC, Kalli KR, Kosel ML, Shridhar V, Rider DN, Liebow M, Cunningham JM, Schildkraut JM, Sellers TA, Goode EL.

PLoS One. 2010 Jan 27;5(1):e8884. doi: 10.1371/journal.pone.0008884.

8.

Inherited determinants of ovarian cancer survival.

Goode EL, Maurer MJ, Sellers TA, Phelan CM, Kalli KR, Fridley BL, Vierkant RA, Armasu SM, White KL, Keeney GL, Cliby WA, Rider DN, Kelemen LE, Jones MB, Peethambaram PP, Lancaster JM, Olson JE, Schildkraut JM, Cunningham JM, Hartmann LC.

Clin Cancer Res. 2010 Feb 1;16(3):995-1007. doi: 10.1158/1078-0432.CCR-09-2553. Epub 2010 Jan 26.

9.

BioGPS: an extensible and customizable portal for querying and organizing gene annotation resources.

Wu C, Orozco C, Boyer J, Leglise M, Goodale J, Batalov S, Hodge CL, Haase J, Janes J, Huss JW 3rd, Su AI.

Genome Biol. 2009;10(11):R130. doi: 10.1186/gb-2009-10-11-r130. Epub 2009 Nov 17.

10.

Association of genetic variation in mitotic kinases with breast cancer risk.

Wang X, Fredericksen ZS, Vierkant RA, Kosel ML, Pankratz VS, Cerhan JR, Justenhoven C, Brauch H; GENICA Consortium, Olson JE, Couch FJ.

Breast Cancer Res Treat. 2010 Jan;119(2):453-62. doi: 10.1007/s10549-009-0404-3. Epub 2009 Apr 30.

11.

Role of genetic polymorphisms and ovarian cancer susceptibility.

Fasching PA, Gayther S, Pearce L, Schildkraut JM, Goode E, Thiel F, Chenevix-Trench G, Chang-Claude J, Wang-Gohrke S, Ramus S, Pharoah P, Berchuck A; OCAC (Ovarian Cancer Association Consortium).

Mol Oncol. 2009 Apr;3(2):171-81. doi: 10.1016/j.molonc.2009.01.008. Epub 2009 Feb 4. Review.

12.

Sampling strategies for tissue microarrays to evaluate biomarkers in ovarian cancer.

Permuth-Wey J, Boulware D, Valkov N, Livingston S, Nicosia S, Lee JH, Sutphen R, Schildkraut J, Narod S, Parker A, Coppola D, Sellers T, Pal T.

Cancer Epidemiol Biomarkers Prev. 2009 Jan;18(1):28-34. doi: 10.1158/1055-9965.EPI-08-0713.

13.

Angiogenesis-related gene expression profile with independent prognostic value in advanced ovarian carcinoma.

Mendiola M, Barriuso J, Redondo A, Mariño-Enríquez A, Madero R, Espinosa E, Vara JA, Sánchez-Navarro I, Hernández-Cortes G, Zamora P, Pérez-Fernández E, Miguel-Martín M, Suárez A, Palacios J, González-Barón M, Hardisson D.

PLoS One. 2008;3(12):e4051. doi: 10.1371/journal.pone.0004051. Epub 2008 Dec 29.

14.

Polymorphisms and clinical outcome in recurrent ovarian cancer treated with cyclophosphamide and bevacizumab.

Schultheis AM, Lurje G, Rhodes KE, Zhang W, Yang D, Garcia AA, Morgan R, Gandara D, Scudder S, Oza A, Hirte H, Fleming G, Roman L, Lenz HJ.

Clin Cancer Res. 2008 Nov 15;14(22):7554-63. doi: 10.1158/1078-0432.CCR-08-0351.

15.

"BRCAness" syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations.

Tan DS, Rothermundt C, Thomas K, Bancroft E, Eeles R, Shanley S, Ardern-Jones A, Norman A, Kaye SB, Gore ME.

J Clin Oncol. 2008 Dec 1;26(34):5530-6. doi: 10.1200/JCO.2008.16.1703. Epub 2008 Oct 27.

PMID:
18955455
16.

The effects of common genetic variants in oncogenes on ovarian cancer survival.

Quaye L, Gayther SA, Ramus SJ, Di Cioccio RA, McGuire V, Hogdall E, Hogdall C, Blaakr J, Easton DF, Ponder BA, Jacobs I, Kjaer SK, Whittemore AS, Pearce CL, Pharoah PD, Song H.

Clin Cancer Res. 2008 Sep 15;14(18):5833-9. doi: 10.1158/1078-0432.CCR-08-0819.

17.

HGF/MET signaling in ovarian cancer.

Zhou HY, Pon YL, Wong AS.

Curr Mol Med. 2008 Sep;8(6):469-80. Review.

PMID:
18781954
18.

ABCB1 (MDR 1) polymorphisms and progression-free survival among women with ovarian cancer following paclitaxel/carboplatin chemotherapy.

Johnatty SE, Beesley J, Paul J, Fereday S, Spurdle AB, Webb PM, Byth K, Marsh S, McLeod H; AOCS Study Group, Harnett PR, Brown R, DeFazio A, Chenevix-Trench G.

Clin Cancer Res. 2008 Sep 1;14(17):5594-601. doi: 10.1158/1078-0432.CCR-08-0606. Erratum in: Clin Cancer Res. 2012 Jan 1;18(1):319-20.

19.

Expression and mutational analysis of MET in human solid cancers.

Ma PC, Tretiakova MS, MacKinnon AC, Ramnath N, Johnson C, Dietrich S, Seiwert T, Christensen JG, Jagadeeswaran R, Krausz T, Vokes EE, Husain AN, Salgia R.

Genes Chromosomes Cancer. 2008 Dec;47(12):1025-37. doi: 10.1002/gcc.20604.

20.

Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome.

Tothill RW, Tinker AV, George J, Brown R, Fox SB, Lade S, Johnson DS, Trivett MK, Etemadmoghadam D, Locandro B, Traficante N, Fereday S, Hung JA, Chiew YE, Haviv I; Australian Ovarian Cancer Study Group, Gertig D, DeFazio A, Bowtell DD.

Clin Cancer Res. 2008 Aug 15;14(16):5198-208. doi: 10.1158/1078-0432.CCR-08-0196.

Supplemental Content

Support Center